NeoGenomics Inc NEO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NEO is a good fit for your portfolio.
News
-
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
-
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
-
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
-
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference
-
NeoGenomics Reports Fourth Quarter and Full Year 2023 Results
-
NeoGenomics Signs Working with Cancer Pledge in Support of Employees
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc. - NEO
-
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
Trading Information
- Previous Close Price
- $13.75
- Day Range
- $13.45–13.85
- 52-Week Range
- $11.05–21.22
- Bid/Ask
- $13.77 / $13.80
- Market Cap
- $1.76 Bil
- Volume/Avg
- 229,608 / 895,085
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.06
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 2,100
- Website
- https://www.neogenomics.com
Comparables
Valuation
|
Metric
|
NEO
|
TIHE
|
300289
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 233.00 |
Price/Book Value | 1.95 | — | 1.45 |
Price/Sales | 3.06 | — | 5.16 |
Price/Cash Flow | 76.99 | — | 19.64 |
Price/Earnings
NEO
TIHE
300289
Financial Strength
|
Metric
|
NEO
|
TIHE
|
300289
|
|---|---|---|---|
Quick Ratio | 5.67 | — | — |
Current Ratio | 6.20 | — | — |
Interest Coverage | −15.50 | — | — |
Quick Ratio
NEO
TIHE
300289
Profitability
|
Metric
|
NEO
|
TIHE
|
300289
|
|---|---|---|---|
Return on Assets (Normalized) | −0.87% | — | — |
Return on Equity (Normalized) | −1.54% | — | — |
Return on Invested Capital (Normalized) | −1.52% | — | — |
Return on Assets
NEO
TIHE
300289
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Wwklfxccz | Hwk | $212.9 Bil | |
DHR
| Danaher Corp | Nlxwthrsb | Nlydqn | $177.5 Bil | |
IQV
| IQVIA Holdings Inc | Xtjrnjv | Sddjbk | $42.6 Bil | |
A
| Agilent Technologies Inc | Pyprqckt | Wtkw | $41.1 Bil | |
IDXX
| IDEXX Laboratories Inc | Jqzrmcfbz | Rfyscs | $40.8 Bil | |
MTD
| Mettler-Toledo International Inc | Tptfxtdwz | Gykdhqy | $26.6 Bil | |
ICLR
| Icon PLC | Jlzkmqqpp | Pkpwp | $24.7 Bil | |
ILMN
| Illumina Inc | Hqczhbrz | Rzzppg | $19.3 Bil | |
WAT
| Waters Corp | Vzsydndmw | Hrly | $19.0 Bil | |
LH
| Laboratory Corp of America Holdings | Zcjbynjmz | Kcltcgl | $17.1 Bil |